Navigation Links
Nasdaq Stays Suspension of Trading in deCODE Stock
Date:4/28/2009

deCODE shares will continue to trade as usual pending Nasdaq listing review

REYKJAVIK, Iceland, April 28 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) announced that it has this evening received a letter from the Nasdaq Listing and Hearing Review Council stating that the Council has called for review the April 22 determination of the Nasdaq Listing Qualifications Panel regarding the delisting of the company's common stock from the Nasdaq Stock Market. Pending the completion of this review the Council has also stayed the Panel's proposed suspension of trading in deCODE common stock mentioned in deCODE's 8-K filing made after the close of the market this afternoon. The company's stock will therefore continue to trade as usual on the Nasdaq Capital Market during the review process.

About deCODE

deCODE is a biopharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM)
'/>"/>

SOURCE deCODE genetics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
3. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
4. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
5. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
6. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. XTL Receives Staff Letter From NASDAQ
9. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 In November 2012, ... Benefit Risk Evaluation Report (PBRER) in a new PSUR – ... post-authorization safety benefit-risk profile of a drug. Adopted in many ... , Present a comprehensive and critical analysis of ... , Highlight any new evidence of the potential ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014 Deep Research Report on ... and in-depth research report on the China Linalool ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:8/18/2014)... Diagnostics Inc. (TSX-V: SQD), a life sciences company that ... microarray diagnostics, today announced it will hold an investor ... ET.  During the call, Andrew ... SQI,s recent commercialization progress and then introduce Dr. ... to the Board of Directors of SQI and also ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3
... Crystal Research Associates, LLC announced today that it ... Inc. (NYSE Amex: CUR ). The full ... .Neuralstem, Inc. ("Neuralstem" or "the Company") is a ... stem cells to treat central nervous system (CNS) diseases. ...
... /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS;,Nasdaq: PXSL ) ... afternoon of Wednesday 8th April 2009. Dr Alan Robertson ... quarter and answer,investor questions. , The ... 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West ...
... April 6 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... from Spectrum Pharmaceuticals, Inc. (Spectrum) in connection with the ... venture to Spectrum for approximately $16.5 million that closed ... on March 2, 2009, related to this transaction, and ...
Cached Biology Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc. 3CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3
(Date:8/20/2014)... and POINT ROBERTS, Washington , ... Play a Key Role in Addressing Security Concerns in the ... a global news source covering leading sectors including biometrics, issues ... market. Jason Peaslee , Managing Partner at ... and Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: ...
(Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
(Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2
... French . , Quebec City, August 25, 2011A diet rich ... according to a study conducted by Universit Laval researchers. The team, ... extent of brain damage following a stroke was reduced by 25% ... study can be found on the website of the journal ...
... DURHAM, N.C. Aerobic exercise is your best bet when ... study finds. When Duke University Medical Center researchers conducted ... combination of the two, they found aerobic exercise to be ... belly fat that,s most damaging to your health. This ...
... have developed the first practical method to create a compound ... naturally in a species of moss found in China, is ... disease in China since the late 1990s and is sold ... memory. Scientists believe it could also potentially combat the effects ...
Cached Biology News:Omega-3s reduce stroke severity 2Aerobic exercise bests resistance training at burning belly fat 2Scientists create natural Alzheimer's-fighting compound in lab 2
... Isolated Sequence) siRNA Test System is designed ... of a potential of any DNA sequence ... RNA interference (RNAi). Current computer-based RNAi target ... probability of selected sequence to be a ...
... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
... This mounting medium is specifically formulated for ... which have been stained with immunohistochemical methods ... ideal for use with chromogens, such as ... organic solvents. Faramount dries completely when slides ...
Biology Products: